People from three major cities across the world have shared their stories on how the new hepatitis C treatment have changed their lives.
A clinical trial has shown that a new drug combination taken over 12 weeks, can effectively treat hepatitis C genotypes 1, 2, 4, 5 and 6.
The first World Hepatitis Summit in Glasgow (2-4 September 2015) was filled with a sense of history as the goal of eliminating viral hepatitis seemed closer than ever before.
South Australia has the lowest rate in the country, for monitoring for people with chronic hepatitis B. Less than two per cent of affected South Australians receive the regular check-ups they need.
ASHM has issued a set of advice for doctors faced with patients asking about importing generic hepatitis C medicines.
Twenty-seven health organisations have published an open letter letter to the Health Minister, Hon. Sussan Ley MP, urging the inclusion of breakthrough hepatitis C cures on the Pharmaceutical Benefits Scheme.
The Glasgow Declaration on Viral Hepatitis - concluding the first World Hepatitis Summit - calls on governments to implement and fund comprehensive hepatitis programmes in line with World Health Assembly Resolution 67.6.
Gilead reports that a combination of sofosbuvir and experimental 'pan-genotypic' NS5A inhibitor velpatasvir (GS-5816) has proven effective regardless of HCV genotype in four late-stage studies.
Four groundbreaking hepatitis C medicines have been recommended for listing on the Pharmaceutical Benefits Scheme (PBS) but so far, no listing date has been confirmed.
1000 Australians die each year from viral hepatitis. Take a look at the animation promoting this year's #TimeForAction campaign.
Many people with hepatitis C would have heard of Greg Jefferys, the Tasmanian man who bypassed the Australian pharmaceutical system and got his treatment drugs from overseas.
Help our annual awareness campaign by putting some bookmarks into letterboxes in your neighbourhood!
